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The risk for reintroduction of some exotic vector-borne 
diseases in Europe has become a hot topic, while the real-
ity of others is neglected at the public health policy level. 
Leishmaniasis is endemic in all southern countries of Eu-
rope, with ≈700 autochthonous human cases reported each 
year (3,950 if Turkey is included). Asymptomatic cases have 
been estimated at 30–100/1 symptomatic case, and leish-
maniasis has up to 25% seroprevalence in domestic dogs. 
Even though leishmaniasis is essentially associated with 
Leishmania infantum and visceral leishmaniasis, new spe-
cies, such as L. donovani and L. tropica, might colonize Eu-
ropean sand ﬂ  y vectors. Drug-resistant L. infantum strains 
might be exported outside Europe through dogs. Despite 
this possibility, no coordinated surveillance of the disease 
exists at the European level. In this review of leishmaniasis 
importance in Europe, we would like to bridge the gap be-
tween research and surveillance and control.
I
n August through September of 2007, a chikungunya 
outbreak occurred in the province of Ravenna, Italy (1). 
The risk for reintroduction of vector-borne diseases in Eu-
rope as a consequence of global warming was highlighted, 
although long-distance tourism, travel, and trade could also 
play major roles in the transcontinental transport of micro-
organisms (2). The European Centre for Disease Control 
is currently assessing the magnitude and importance of 
vector-borne diseases in Europe, focusing on Lyme disease, 
tick-borne encephalitis, leptospirosis, malaria, plague, tula-
remia, viral hemorrhagic fevers, hantavirus, and West Nile 
fever. Concern about the impact of global warming and the 
spread of arthropod-borne diseases and other infectious 
agents in Europe is justiﬁ  able. However, existing autoch-
thonous vector-borne infections should not be forgotten 
or ignored, which may be the case, as illustrated here for 
leishmaniasis.
Leishmaniasis in Europe
Leishmaniasis is a major vector-borne disease, which 
is endemic to 88 countries and is the only tropical vector-
borne disease that has been endemic to southern Europe for 
decades. In southern Europe, most of the reported cases are 
due to zoonotic visceral leishmaniasis (VL), which is the 
most dangerous form and is lethal when untreated. Cuta-
neous leishmaniasis (CL), which is more benign than VL, 
is also present. Incidence of leishmaniasis in humans is 
relatively low, ranging from 0.02/100,000 to 0.49/100,000 
(8.53/100,000 including Turkey). We estimate that this cor-
responds to a total of ≈700 reported new cases per year for 
southern European countries (3,950 if Turkey is included; 
Table and Figure). However, autochthonous leishmaniasis 
appears not to be limited to the Mediterranean region any-
more. It has spread northward, as shown by the recent re-
ports of indigenous VL cases in northern Italy and southern 
Germany (8,9).
However, these numbers are misleading for several rea-
sons. First, data from patients infected in southern Europe, 
but diagnosed elsewhere, are not taken into consideration. 
For instance, a leishmaniasis reference center established 
on a voluntary basis in Germany identiﬁ  ed within 2 years 
70 cases of leishmaniasis. Of the 27 VL case-patients, most 
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(17) had been infected within European Union boundaries: 
Spain, Portugal, Greece, or France (10). Five cases were 
in children. Similarly, a retrospective study in the Hospital 
for Tropical Diseases in London showed that most of the 
imported VL case-patients in the United Kingdom were 
adult men touring the Mediterranean (11). Second, in the 
absence of public health surveillance at the European level, 
underreporting is common (see the Leishmaniasis and the 
Globalization of Neglect section). Third, asymptomatic 
infections may be common in some regions: for 1 clini-
cal case of VL, there may be 30–100 subclinical infections 
(12). This underreporting can have major consequences for 
blood banks: blood from donors living in areas of endemic-
ity in southern France and Greece had 3.4% and 15% sero-
positivity, respectively (13,14). In addition, 22.1% of blood 
donors in a highly disease-endemic area from Spain were 
PCR positive for leishmaniasis (15). Furthermore, asymp-
tomatic infections may progress to severe clinical forms in 
immunocompromised persons, for example, in AIDS pa-
tients (16). Fourth, the etiologic agent of southern Euro-
pean VL, Leishmania infantum, is also infecting dogs (with 
a seroprevalence of up to 34% in areas of Spain where the 
disease is highly endemic) (Table). Dogs with leishmania-
sis infections are generally very sick, causing a major prob-
lem in southern Europe (e.g., ≈5,000 clinical cases occur 
each year in France) (Table). However, sick as well as as-
ymptomatic dogs also represent a risk for humans, as they 
constitute the major reservoir of the parasite on which sand 
ﬂ  y vectors may feed and transmit the infection.
Import–Export Balance of European Leishmaniasis
In addition to the reality of autochthonous leishma-
niasis in Europe, the risk for introduction of new species 
through travelers or immigrants from countries where 
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Table. Leishmaniasis situation in 7 disease-endemic countries of Europe (including Turkey)* 
Human leishmaniasis 
Country  Notification status 
Current information from 
reference centers  
(2000–2006) 
VL + CL 
incidence x 
100,000†
Imported cases 
(VL + CL) 
Canine
leishmaniasis
Portugal‡ Compulsory for VL  |22 VL cases/y recorded at 
IHMT
0.07–0.17 |2 cases/y 
recorded at IHMT 
Average 20% 
seroprevalence in 
disease-endemic
areas (3)
Spain§ Compulsory in 12/17 
autonomous communities; 
20%–45% underreporting for 
VL, |100% for CL (4)
|100 VL cases/y recorded 
by National Epidemiologic 
Surveillance Network, 
RENAVE
0.18–0.29 |5 cases/y 
recorded at ISCIII 
Average 8.5% 
seroprevalence (5)
France¶ Not  compulsory,  but 
spontaneous reports at UMON 
|24 VL + CL cases/y 
reported at UMON 
0.02–0.19 |65 cases/y 
recorded at 
UMON
Seroprevalence in 
disease-endemic
areas of southern 
France 4%–20%# 
Italy**  Compulsory for both VL and 
CL, but CL underreported 
|200 VL cases/y recorded at 
ISS; |300 CL cases/y 
estimated by ISS 
0.15–0.38 |8 cases/y 
recorded at ISS 
Average 15% 
seroprevalence in 
peninsular Italy; 
average 2% 
seroprevalence in 
continental Italy (6)
Greece††  Compulsory for both VL and 
CL, but underreported 
|21 VL cases/y notified  0.06–0.49 Unknown Average
seroprevalence
25% in disease-
endemic areas (7)
Cyprus‡‡  Compulsory for both VL and 
CL, but 
underreported 
5 VL + CL cases recorded in 
2006
0.25–0.47 Unknown Average
seroprevalence
20% in disease-
endemic areas 
Turkey§§  Compulsory for both VL and 
CL
|37 VL cases/y and |2,300
CL cases/y notified 
1.6–8.53 Unknown Average  15.7% 
seroprevalence
*Authors’ institutions are national reference laboratories for leishmaniasis diagnosis and surveillance and rely on consolidated countrywide networks of 
collaborating clinical health centers. Diagnosis records are cross-checked with case notifications to provide more realistic figures and estimates. VL, 
visceral leishmaniasis; CL, cutaneous Leishmaniasis; WHO, World Health Organization. 
†WHO-EURO, WHO Europe, 1996–2005; http://data.euro.who.int/CISID.  
‡Instituto de Higiene e Medicina Tropical (IHMT), Lisbon, Portugal. 
§Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 
¶Université de Montpellier (UMON), data from Centre National de Référence des Leishmania, Montpellier, France. 
#Source: retrospective canine leishmaniasis database, Centre National de Référence des Leishmania. 
**Istituto Superiore di Sanità (ISS), Rome, Italy. 
††Hellenic Pasteur Institute (HPI), Athens, Greece. 
‡‡National Reference Laboratory for Animal Health (VS), Nicosia, Cyprus. 
§§Ege University (EUMS-DP), Izmir, Turkey. Neglect of Leishmaniasis, Europe
non-European species are endemic should also be consid-
ered. However, the probability that these species could 
enter in a transmission cycle is relatively low. The prob-
ability depends on contact between infected persons and 
sand ﬂ  ies, the capacity of the infected person to act as 
reservoir, and the susceptibility of European sand ﬂ  ies to 
the different Leishmania species. For most species, hu-
mans are generally a transmission dead-end. However, 
for 2 species, the risk might theoretically be higher: L. 
tropica, which is causing CL in Africa, the Middle East, 
and Southwest Asia, and L. donovani, the etiologic agent 
of VL in East Africa and the Indian subcontinent. These 
2 species are indeed associated with an anthroponotic 
transmission cycle. On one hand, L. donovani, which is 
transmitted by a different species of sand ﬂ  y outside Eu-
rope, might be hosted by most European sand ﬂ  ies, except 
Phlebotomus papatasi and P. sergenti (17). On the other 
hand, L. tropica, which has more stringent requirements 
in terms of vector, would need P. sergenti, which was re-
ported in several places in southern Europe, from Portugal 
(18) to Cyprus (19). L. tropica was indeed encountered 
in Greece (20), and according to a very recent report, the 
ﬁ  rst autochthonous cases of L. donovani in Europe have 
been detected in Cyprus (21). The clinical phenotype as-
sociated with both species needs also to be considered for 
an exhaustive risk evaluation. L. tropica causes lesions 
that are generally more difﬁ  cult to treat with antimonial 
drugs (22), whereas L. donovani is considered to be more 
aggressive than L. infantum and often does not respond to 
treatment with ﬁ  rst-line drugs (23).
In addition to being concerned about importation and 
spread of exotic Leishmania species in Europe, exportation 
should also be considered. The best known historical ex-
ample of the spread of leishmaniasis is the migration of 
L. infantum from Europe to Latin America, where it colo-
nized in Lutzomyia longipalpis and is now causing a seri-
ous public health problem (>3,500 cases of VL per year in 
Brazil) (24). This spread is thought to have been caused 
by conquistadores’ dogs (25). Another and current ex-
ample concerns the L. major/L. infantum hybrids recently 
described in HIV-positive VL patients from Portugal (26). 
Indeed, these hybrids were shown to be able to develop in 
P. papatasi (27), a vector that is widespread in Europe, Af-
rica, and Asia. Considering the reservoir role of HIV–co-
infected patients and the peridomestic and anthropophilic 
nature of P. papatasi, these hybrid strains might circulate 
by using this sand ﬂ  y vector, thereby increasing the risk of 
their spreading into new foci throughout the broad range of 
P. papatasi distribution (27). Finally, the way Europe deals 
with its leishmaniasis public and animal health problem 
can still have major consequences for the rest of the world. 
Miltefosine, one of the few available antileishmania drugs, 
has been recently launched in the market for canine leish-
maniasis treatment in Portugal, Spain, Italy, Greece, and 
Cyprus. Because dogs are never cured parasitologically 
and given the long half-life of the drug, the lack of Euro-
pean policy might contribute to the emergence of parasites 
resistant to miltefosine. This resistance could be a problem 
for European human patients, as miltefosine is being used 
on a compassionate basis in several European AIDS co-
infected patients unresponsive to amphotericin B or pen-
tavalent antimonials (28,29). Furthermore, if dogs infected 
with miltefosine-resistant strains were to migrate to Latin 
America, where several countries have registered the drug 
for human use (currently Colombia, Guatemala, Argentina, 
Venezuela, Paraguay, Ecuador, and Honduras; 30), the im-
pact might be greater.
Leishmaniasis and the Globalization of Neglect
Twelve million persons have leishmaniasis, and 
500,000 new cases of VL occur each year. More than 
50,000 die of this disease each year. The disease is spread-
ing because of several risk factors, climate being only 
one. Humanmade changes to the environment and popu-
lation movements (for economic or political reasons) may 
lead to alterations in the range and densities of the vectors 
and reservoirs, increasing human exposure to infected 
sand ﬂ  ies. Urbanization of leishmaniasis becomes more 
common and in conjunction with the ruralization of HIV/
AIDS, it contributes to increase the problem of co-infec-
tions in contexts where access to highly active antiretro-
viral therapy is not the same as in industrialized countries. 
Leishmania spp. have already become resistant to antimo-
nial drugs (the ﬁ  rst-line drug in many developing coun-
tries) in some regions and may soon become resistant to 
miltefosine (23). Despite this increasing resistance, leish-
maniasis is one of the most neglected diseases in develop-
ing countries, along with others like sleeping sickness or 
Chagas disease. Leishmaniasis is a disease for which we 
lack effective, affordable, and easy to use drugs, and the 
pharmaceutical industry has had few incentives to engage 
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Figure. Leishmaniasis in southern Europe. Distribution of the 
endemic disease; relative proportion of autochthonous (visceral, 
cutaneous) and imported human cases and seroprevalence in 
dogs (from data reported in Table). PERSPECTIVE
in their development. In addition, leishmaniasis surveil-
lance and control are also neglected. One of the main 
reasons for this neglect is that in developing countries, 
leishmaniasis is a disease of the poor. Risk for infection 
and clinical development are mediated by poverty, while 
leishmaniasis diagnosis and treatment are expensive and 
may lead to further impoverishment and reinforcement of 
the vicious cycle of disease and poverty (31).
In Europe, physicians are sometimes ill-informed on 
the diagnosis and treatment of leishmaniasis. In France, a 
telephone advice line was created in 2006 by the National 
Reference Centre of Leishmania to help physicians in their 
therapeutic diagnosis. A study in Germany, a non–disease-
endemic country, showed that the median time between 
symptom onset and correct diagnosis was 85 and 61 days 
in case-patients of VL and CL, respectively (32). This value 
was lower in a leishmaniasis-endemic area, such as south-
ern Italy (35 days, [33]). VL, which was initially a pediat-
ric disease in Europe (hence the name of L. infantum), only 
began to gain attention when the co-infection of HIV/AIDS 
was documented. Between the late 1980s and early 2001, 
>1,900 cases were reported in southwestern Europe (16). 
Even though it was reported that both pathogens could be 
transmitted through sharing of needles among intravenous 
drug users (34), in many cases of co-infection, the parasite 
was already present at the time of HIV infection, which indi-
cates that HIV infection would have an unmasking effect on 
the true endemicity of Leishmania infection. In other words, 
the wave of Leishmania/HIV co-infection showed that L. in-
fantum could behave as an opportunistic parasite, with many 
asymptomatic carriers (12), and with the clinical syndromes 
being only the tip of the iceberg. Because of the highly ac-
tive antiretroviral therapy, cases of co-infection generally 
decreased in the region, with the exception of Portugal (35).
Notiﬁ  cation of VL varies according to the country. It 
does not belong to the list of 30 notiﬁ  able diseases in France. 
However, notiﬁ  cation is compulsory in Greece, Italy, and 
Portugal, though only obligatory in 12 of 17 autonomous 
communities of Spain. Underreporting is common. In Por-
tugal, for instance, 76 cases of autochthonous VL were ofﬁ  -
cially reported at the country level from 2000 through 2005. 
During the same period, 127 cases (+67%) were observed 
in the Institute of Tropical Medicine of Lisboa (Table). In 
the case of autochthonous cutaneous leishmaniasis, consol-
idated data are lacking, but this clinical form is deﬁ  nitely 
underreported because of its benign nature and the fact that 
it usually does not require hospitalization. Nonetheless, 
leishmaniasis is not a disease placed under public health 
surveillance at the European level. It does not even belong 
to the package of rare diseases considered as a priority in 
the Public Health Programme 2003–2008. (Rare diseases, 
including those of genetic origin, are life-threatening or 
chronically debilitating diseases that are of such low preva-
lence [<5/10,000 persons] that special combined efforts are 
needed to address them so as to prevent signiﬁ  cant illness 
or perinatal or early deaths or a considerable reduction in a 
person’s quality of life or socioeconomic potential.) At the 
regional level, the only dedicated network of surveillance 
was the one launched by the World Health Organization 
and the Joint United Nations Programme on HIV/AIDS in 
1993 for the surveillance of Leishmania/HIV co-infections, 
which essentially involved European countries as well as 
some developing countries.
The low-proﬁ  le perception seen for human leishmania-
sis differs dramatically from the veterinary world’s percep-
tion. The high incidence of canine leishmaniasis in south-
ern Europe makes Leishmania one of the main dog killers 
in the region, and private veterinarians are well aware of 
it. Dogs are treated individually to protect from sand ﬂ  y 
bites, and those diagnosed as infected are considered ex-
tremely difﬁ  cult to treat. Speciﬁ  c web sites are available 
for owners of infected dogs to discuss and compare treat-
ment regimens and pose questions to veterinarians. Several 
pharmaceutical companies are investing in research and de-
velopment of vaccines, drugs, and topical insecticides for 
speciﬁ  c cure and prevention of canine leishmaniasis. This 
high-proﬁ  le perception, however, drops when dogs must 
be treated as the reservoir of human leishmaniasis. For 
instance, the issue of notiﬁ  cation is treated differently in 
various leishmaniasis–endemic countries, but even where 
notiﬁ  cation is compulsory (i.e., Italy and Spain), it is not 
a common practice. In Italy, the network Leishmap is cur-
rently monitoring the spread of canine leishmaniasis and 
vectors in northern Italy. Leishmap is a scientiﬁ  c network, 
supported by a private company (36). Furthermore, private 
interests are sometimes at odds with public health goals. 
Drugs for leishmaniasis are not regulated in the veterinary 
market, and medications intended for use in humans, such 
as Ambisome, are used in domestic pets, with the poten-
tial risk that they might be a source for the emergence and 
spreading of resistant strains.
Countering the Neglect
Since 2001, several research consortia gathered scien-
tists from Euro-Mediterranean countries (www.leishrisk.
net). These consortia and other research groups generated 
knowledge, tools, and education packages and led to a solid 
European research network dedicated to the study of leish-
maniasis. Bridging research with surveillance and control 
is an issue of dialogue and advocacy. On one hand, health 
professionals need to be in close contact with scientists to 
help translate basic research into relevant and applicable 
tools. For instance, sequencing the whole genome of Leish-
mania represented a technologic challenge, but the next 
challenge is to exploit this sequencing for the beneﬁ  t of the 
patient (www.leishrisk.net). On the other hand, scientists 
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must market their results to inﬂ  uence health policy. Chang-
es in health policy are being made; during manuscript revi-
sion, we were informed of the selection of leishmaniasis 
among the priority zoonoses addressed by the Episouth 
network (www.leishrisk.net).
Deciding health policy is a complex social, economic, 
and political interrelationship that is much broader than 
leishmaniasis alone (or even infectious diseases generally). 
However, if Europe justiﬁ  ably wants to invest more in sur-
veillance of vector-borne diseases, the time has come to 
recognize its real impact on both animal and human health 
and include leishmaniasis as one of these diseases.
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